News

Johnson & Johnson: First Look At Q1 Earnings - Solid Quarter Will Calm Nerves
Johnson & Johnson’s Q1 2025 earnings reveal growth in sales and EPS, boosted by MedTech and Pharma. Click for my updated look at JNJ and its most recent news.
pharmaphorum3d
Axsome bounces back as FDA clears depression drug
The FDA has cleared Auvelity (dextromethorphan ... That status goes to Johnson & Johnson's Spravato (esketamine), which was approved in March 2019 and is administered as a nasal spray twice ...
Denver76d
'It saved my life': Patient, psychiatrist believe ketamine therapy is integral in changing trauma responses
Ketamine is only approved by the FDA as an anesthetic, but there is growing interest in using ketamine products to treat ...
NPR5d
Shots
April 11, 2025 • Surgeons at NYU Langone Health in New York City had to remove a genetically modified pig kidney from Towana Looney, 53, of Gadsden, Ala., because her body rejected the organ ...